Post-herpetic neuralgia: 5% lidocaine medicated plaster, pregabalin, or a combination of both? A randomized, open, clinical effectiveness study

References

• Weinberg JM. Herpes zoster: epidemiology, natural history, and common complications. J Am Acad Dermatol 2007;57:S130-5
   PubMed Web of Science ®Google Scholar
• Zin CS, Nissen LM, Smith MT, et al. An update on the pharmacological management of post-herpetic neuralgia and painful diabetic neuropathy. CNS Drugs 2008;22:417-42
   PubMed Web of Science ®Google Scholar
• Cruccu G, Anand P, Attal N, et al. EFNS guidelines on neuropathic pain assessment. Eur J Neurol 2004;11:153-62
   PubMed Web of Science ®Google Scholar
• Fields HL, Rowbotham M, Baron R. Postherpetic neuralgia: irritable nociceptors and deafferentation. Neurobiol Dis 1998;5:209-27
   PubMed Web of Science ®Google Scholar
• Argoff CE, Katz N, Backonja M. Treatment of postherpetic neuralgia: a review of therapeutic options. J Pain Symptom Manage 2004;28:396-411
   PubMed Web of Science ®Google Scholar
• Dworkin RH, O'Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 2007;132:237-51
   PubMed Web of Science ®Google Scholar
• Gottrup H, Bach FW, Juhl G, Jensen TS. Differential effect of ketamine and lidocaine on spontaneous and mechanical evoked pain in patients with nerve injury pain. Anesthesiology 2006;104:527-36
   PubMed Web of Science ®Google Scholar
• Finnerup NB, Otto M, Jensen TS, et al. An evidence-based algorithm for the treatment of neuropathic pain. MedGenMed 2007;9:36
   PubMedGoogle Scholar
• Finnerup NB, Otto M, McQuay HJ, et al. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 2005;118:289-305
   PubMed Web of Science ®Google Scholar
• Gammaitoni AR, Davis MW. Pharmacokinetics and tolerability of lidocaine patch 5% with extended dosing. Ann Pharmacother 2002;36:236-40
   PubMed Web of Science ®Google Scholar
• Rowbotham MC, Davies PS, Verkempinck C, et al. Lidocaine patch: double-blind controlled study of a new treatment method for post-herpetic neuralgia. Pain 1996;65:39-44
   PubMed Web of Science ®Google Scholar
• Dalpiaz AS, Lordon SP, Lipman AG. Topical lidocaine patch therapy for myofascial pain. J Pain Palliat Care Pharmacother 2004;18:15-34
   PubMedGoogle Scholar
• Electronic Medicines Compendium. Versatis 5% medicated plaster. Summary of Product Characteristics. [last accessed 25 Aug 2009]; Available from: http://emc.medicines.org.uk/medicine/19291/SPC/Versatis+5%25+Medicated+Plaster
   Google Scholar
• Wasner G, Kleinert A, Binder A, et al. Postherpetic neuralgia: topical lidocaine is effective in nociceptor-deprived skin. J Neurol 2005;252:677-86
   PubMed Web of Science ®Google Scholar
• Campbell BJ, Rowbotham M, Davies PS, et al. Systemic absorption of topical lidocaine in normal volunteers, patients with post-herpetic neuralgia, and patients with acute herpes zoster. J Pharm Sci 2002;91:1343-50
   PubMed Web of Science ®Google Scholar
• Binder A, Bruxelle J, Rogers P, et al. Topical 5% lidocaine (lignocaine) medicated plaster treatment for post-herpetic neuralgia: results of a double-blind, placebo-controlled, multinational efficacy and safety trial. Clin Drug Investig 2009;29:393-408
   PubMed Web of Science ®Google Scholar
• Galer BS, Jensen MP, Ma T, et al. The lidocaine patch 5% effectively treats all neuropathic pain qualities: results of a randomized, double-blind, vehicle-controlled, 3-week efficacy study with use of the neuropathic pain scale. Clin J Pain 2002;18:297-301
   PubMed Web of Science ®Google Scholar
• Galer BS, Rowbotham MC, Perander J, et al. Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study. Pain 1999;80:533-8
   PubMed Web of Science ®Google Scholar
• Meier T, Wasner G, Faust M, et al. Efficacy of lidocaine patch 5% in the treatment of focal peripheral neuropathic pain syndromes: a randomized, double-blind, placebo-controlled study. Pain 2003;106:151-8
   PubMed Web of Science ®Google Scholar
• Galer BS, Gammaitoni AR. More than 7 years of consistent neuropathic pain relief in geriatric patients. Arch Intern Med 2003;163:628
   PubMed Web of Science ®Google Scholar
• Hans G, Sabatowski R, Binder A, et al. Efficacy and tolerability of a 5% lidocaine medicated plaster for the topical treatment of post-herpetic neuralgia: results of a long-term study. Curr Med Res Opin 2009;25:1295-305
   PubMed Web of Science ®Google Scholar
• Wilhelm IR, Tzabazis A, Likar R, et al. Long-term treatment of neuropathic pain with a 5% lidocaine medicated plaster. Eur J Anaesthesiol 2010;27:169-73
   PubMed Web of Science ®Google Scholar
• Dworkin RH, Corbin AE, Young JP, Jr., et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 2003;60:1274-83
   PubMed Web of Science ®Google Scholar
• Sabatowski R, Galvez R, Cherry DA, et al. Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. Pain 2004;109:26-35
   PubMed Web of Science ®Google Scholar
• van Seventer R, Feister HA, Young JP Jr., et al. Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: a 13-week, randomized trial. Curr Med Res Opin 2006;22:375-84
   PubMed Web of Science ®Google Scholar
• Electronic Medicines Compendium. Lyrica capsules. Summary of Product Characteristics. [last accessed 20 Aug 2009]; Available from: http://emc.medicines.org.uk/document.aspx?documentid=14651
   Google Scholar
• Baron R, Mayoral V, Leijon G, et al. 5% lidocaine medicated plaster versus pregabalin in post-herpetic neuralgia and diabetic polyneuropathy: an open-label, non-inferiority two-stage RCT study. Curr Med Res Opin 2009;25:1663-76
   PubMed Web of Science ®Google Scholar
• Baron R, Mayoral V, Leijon G, et al. Efficacy and safety of combination therapy with 5% lidocaine medicated plaster and pregabalin in post-herpetic neuralgia and diabetic polyneuropathy. Curr Med Res Opin 2009;25:1677-87
   PubMed Web of Science ®Google Scholar
• Farrar JT, Young JP Jr., LaMoreaux L, et al. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001;94:149-58
   PubMed Web of Science ®Google Scholar
• Dworkin RH, Turk DC, Farrar JT, et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 2005;113:9-19
   PubMed Web of Science ®Google Scholar
• Rowbotham M, Harden N, Stacey B, et al. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 1998;280:1837-42
   PubMed Web of Science ®Google Scholar
• Melzack R. The short-form McGill Pain Questionnaire. Pain 1987;30:191-7
   PubMed Web of Science ®Google Scholar
• Bouhassira D, Attal N, Fermanian J, et al. Development and validation of the Neuropathic Pain Symptom Inventory. Pain 2004;108:248-57
   PubMed Web of Science ®Google Scholar
• North Coast Medical Inc. Touch-Test Sensory Evaluator (5.46). Product Code NC12775-16. 2008 [last accessed 13 Mar 2009]; Available from: http://www.ncmedical.com/item_1278.html
   Google Scholar
• Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83
   PubMed Web of Science ®Google Scholar
• EuroQol - a new facility for the measurement of health-related quality of life. The EuroQoL Group. Health Policy 1990;16:199-208
   PubMed Web of Science ®Google Scholar
• Dolan P, Gudex C, Kind P, et al. The time trade-off method: results from a general population study. Health Econ 1996;5:141-54
   PubMed Web of Science ®Google Scholar
• Dolan P, Gudex C, Kind P, et al. A social tarif for EuroQol: results from a UK general population survey. Centre for Health Economics, York Health Economics Consortium and NHS Centre for Reviews and Dissemination Discussion paper 138. York: University of York; 1995
   Google Scholar
• Breslow NE, Day NE. Statistical methods in cancer research. Volume I - The analysis of case-control studies. IARC Sci Publ 1980:5-338
   Google Scholar
• Hempenstall K, Nurmikko TJ, Johnson RW, et al. Analgesic therapy in postherpetic neuralgia: a quantitative systematic review. PLoS Med 2005;2:e164. Epub 2005 Jul 26]
   Google Scholar
• Moore RA, Straube S, Wiffen PJ, et al. Pregabalin for acute and chronic pain in adults. Cochrane Database of Systematic Reviews 2009, Issue 3. Art. No.: CD007076. DOI: 10.1002/14651858.CD007076.pub2
   Google Scholar
• Bland JM, Altman DG. Regression towards the mean. BMJ 1994;308:1499
   PubMed Web of Science ®Google Scholar
• Kroenke K, West SL, Swindle R, et al. Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial. JAMA 2001;286:2947-55
   PubMed Web of Science ®Google Scholar
• Gilron I, Bailey JM, Tu D, et al. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med 2005;352:1324-34
   PubMed Web of Science ®Google Scholar
• Hanna M, O'Brien C, Wilson MC. Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients. Eur J Pain 2008;12:804-13
   PubMed Web of Science ®Google Scholar
• White WT, Patel N, Drass M, et al. Lidocaine patch 5% with systemic analgesics such as gabapentin: a rational polypharmacy approach for the treatment of chronic pain. Pain Med 2003;4:321-30
   PubMed Web of Science ®Google Scholar